Evidence map›Paper›PMID 34666516›Full record

ReviewExperimental biology and medicine (Maywood, N.J.)2021

Islet cell encapsulation - Application in diabetes treatment.

Amoge Opara, Alec Jost, Sam Dagogo-Jack, Emmanuel C Opara

Abstract readReview
In one paragraph

Review in Experimental biology and medicine (Maywood, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Amoge OparaDiabetes Section, Biologics Delivery Technologies, Reno, NV 89502, USA.
Alec JostWake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.ORCID 0000-0003-2628-3072
Sam Dagogo-JackDivision of Endocrinology, Diabetes & Metabolism, University of Tennessee Health Science Center, Memphis, TN 38103, USA.ORCID 0000-0001-5318-9677
Emmanuel C OparaDiabetes Section, Biologics Delivery Technologies, Reno, NV 89502, USA.

Funding

Post-DPP Followup StudiesU01DK048411 · NIDDK · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI DAGOGO-JACK, M.D., D.SC., SAMUEL · 1994 to 2022
$9.2M
Ceramides and Sphingolipids as Predictors of Incident DysglycemiaR01DK128129 · NIDDK · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI DAGOGO-JACK, M.D., D.SC., SAMUEL, MANDAL, NAWAJES · 2021 to 2024
$2.0M
Effects of cell-based hormone therapy on LV diastolic dysfunction and hypertrophy progression after mid-life estrogen lossR21AG061588 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI GROBAN, LEANNE, OPARA, EMMANUEL C. · 2019 to 2020
$436k
Tissue Engineering and Regenerative Medicine Undergraduate Research Addressing Challenges In Diabetes, Kidney, Urologic and Hematologic DiseasesR25DK121572 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI OPARA, EMMANUEL C. · 2019 to 2019
$99k
NIA NIH HHS R21 AG061588NIDDK NIH HHS R01 DK128129NIDDK NIH HHS R25 DK121572NIDDK NIH HHS U01 DK048411
6 · The paper itself

Abstract

In this minireview, we briefly outline the hallmarks of diabetes, the distinction between type 1 and type 2 diabetes, the global incidence of diabetes, and its associated comorbidities. The main goal of the review is to highlight the great potential of encapsulated pancreatic islet transplantation to provide a cure for type 1 diabetes. Following a short overview of the different approaches to islet encapsulation, we provide a summary of the merits and demerits of each approach of the encapsulation technology. We then discuss various attempts to clinical translation with each model of encapsulation as well as the factors that have mitigated the full clinical realization of the promise of the encapsulation technology, the progress that has been made and the challenges that remain to be overcome. In particular, we pay significant attention to the emerging strategies to overcome these challenges. We believe that these strategies to enhance the performance of the encapsulated islet constructs discussed herein provide good platforms for additional work to achieve successful clinical translation of the encapsulated islet technology.

Indexed as

Diabetes Mellitus, Type 1HumansIslets of Langerhans TransplantationbioengineeringDiabetesencapsulationinsulin deliveryislets

Identifiers

PMID34666516
PMCPMC8669170

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.